Status of Propranolol for Treatment of Infantile Hemangioma and Description of a Randomized Clinical Trial
Objectives: Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) th...
Saved in:
Published in | Annals of otology, rhinology & laryngology Vol. 120; no. 10; pp. 686 - 695 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Los Angeles, CA
SAGE Publications
01.10.2011
Annals Publishing Compagny SAGE PUBLICATIONS, INC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives:
Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH.
Methods:
Ovid Medline and PubMed searches were completed for the MeSH keywords “propranolol” and “hemangioma.” Forty-nine English-language articles were published between June 2008 and September 2010, and 28 of these reported data from a total of 213 patients. Only 6 studies treated more than 10 patients, and these were selected for review in detail (154 patients).
Results:
The treatment was initiated during infancy in 92.9% of patients (mean, 4.5 months). Sixty-five percent of patients were treated with 2 mg/kg per day, and 25.3% with 3 mg/kg per day. Patients were monitored overnight at initiation of treatment in 3 series (59 patients), for 4 to 6 hours as outpatients in 2 series (62 patients), and initially as inpatients but later as outpatients in 1 series (32 patients). Propranolol was used as sole therapy in about two thirds of patients (103 patients). Treatment was ongoing in 46% of patients at the time of publication. The average treatment duration in the remaining patients was 5.1 months. Rebound growth occurred in 21% of patients after a mean of 4.3 months of therapy. Adverse events occurred in 18.1% of patients and included hypotension in 6, somnolence in 6, wheezing in 4, insomnia, agitation, and/or nightmares in 6, cool hands or night sweats in 2, gastroesophageal reflux in 3, and psoriasis-like rash in 1. All authors reported a favorable outcome with propranolol, but the definition of efficacy was not standardized.
Conclusions:
Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication. |
---|---|
AbstractList | Objectives:
Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH.
Methods:
Ovid Medline and PubMed searches were completed for the MeSH keywords “propranolol” and “hemangioma.” Forty-nine English-language articles were published between June 2008 and September 2010, and 28 of these reported data from a total of 213 patients. Only 6 studies treated more than 10 patients, and these were selected for review in detail (154 patients).
Results:
The treatment was initiated during infancy in 92.9% of patients (mean, 4.5 months). Sixty-five percent of patients were treated with 2 mg/kg per day, and 25.3% with 3 mg/kg per day. Patients were monitored overnight at initiation of treatment in 3 series (59 patients), for 4 to 6 hours as outpatients in 2 series (62 patients), and initially as inpatients but later as outpatients in 1 series (32 patients). Propranolol was used as sole therapy in about two thirds of patients (103 patients). Treatment was ongoing in 46% of patients at the time of publication. The average treatment duration in the remaining patients was 5.1 months. Rebound growth occurred in 21% of patients after a mean of 4.3 months of therapy. Adverse events occurred in 18.1% of patients and included hypotension in 6, somnolence in 6, wheezing in 4, insomnia, agitation, and/or nightmares in 6, cool hands or night sweats in 2, gastroesophageal reflux in 3, and psoriasis-like rash in 1. All authors reported a favorable outcome with propranolol, but the definition of efficacy was not standardized.
Conclusions:
Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication. Objectives: Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH. Methods: Ovid Medline and PubMed searches were completed for the MeSH keywords “propranolol” and “hemangioma.” Forty-nine English-language articles were published between June 2008 and September 2010, and 28 of these reported data from a total of 213 patients. Only 6 studies treated more than 10 patients, and these were selected for review in detail (154 patients). Results: The treatment was initiated during infancy in 92.9% of patients (mean, 4.5 months). Sixty-five percent of patients were treated with 2 mg/kg per day, and 25.3% with 3 mg/kg per day. Patients were monitored overnight at initiation of treatment in 3 series (59 patients), for 4 to 6 hours as outpatients in 2 series (62 patients), and initially as inpatients but later as outpatients in 1 series (32 patients). Propranolol was used as sole therapy in about two thirds of patients (103 patients). Treatment was ongoing in 46% of patients at the time of publication. The average treatment duration in the remaining patients was 5.1 months. Rebound growth occurred in 21% of patients after a mean of 4.3 months of therapy. Adverse events occurred in 18.1% of patients and included hypotension in 6, somnolence in 6, wheezing in 4, insomnia, agitation, and/or nightmares in 6, cool hands or night sweats in 2, gastroesophageal reflux in 3, and psoriasis-like rash in 1. All authors reported a favorable outcome with propranolol, but the definition of efficacy was not standardized. Conclusions: Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication. Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH. Ovid Medline and PubMed searches were completed for the MeSH keywords "propranolol" and "hemangioma." Forty-nine English-language articles were published between June 2008 and September 2010, and 28 of these reported data from a total of 213 patients. Only 6 studies treated more than 10 patients, and these were selected for review in detail (154 patients). The treatment was initiated during infancy in 92.9% of patients (mean, 4.5 months). Sixty-five percent of patients were treated with 2 mg/kg per day, and 25.3% with 3 mg/kg per day. Patients were monitored overnight at initiation of treatment in 3 series (59 patients), for 4 to 6 hours as outpatients in 2 series (62 patients), and initially as inpatients but later as outpatients in 1 series (32 patients). Propranolol was used as sole therapy in about two thirds of patients (103 patients). Treatment was ongoing in 46% of patients at the time of publication. The average treatment duration in the remaining patients was 5.1 months. Rebound growth occurred in 21% of patients after a mean of 4.3 months of therapy. Adverse events occurred in 18.1% of patients and included hypotension in 6, somnolence in 6, wheezing in 4, insomnia, agitation, and/or nightmares in 6, cool hands or night sweats in 2, gastroesophageal reflux in 3, and psoriasis-like rash in 1. All authors reported a favorable outcome with propranolol, but the definition of efficacy was not standardized. Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication. Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome. Our secondary objective was to describe a randomized, controlled, single-blinded trial comparing propranolol to prednisolone for treatment of IH. Ovid Medline and PubMed searches were completed for the MeSH keywords "propranolol" and "hemangioma." Forty-nine English-language articles were published between June 2008 and September 2010, and 28 of these reported data from a total of 213 patients. Only 6 studies treated more than 10 patients, and these were selected for review in detail (154 patients). The treatment was initiated during infancy in 92.9% of patients (mean, 4.5 months). Sixty-five percent of patients were treated with 2 mg/kg per day, and 25.3% with 3 mg/kg per day. Patients were monitored overnight at initiation of treatment in 3 series (59 patients), for 4 to 6 hours as outpatients in 2 series (62 patients), and initially as inpatients but later as outpatients in 1 series (32 patients). Propranolol was used as sole therapy in about two thirds of patients (103 patients). Treatment was ongoing in 46% of patients at the time of publication. The average treatment duration in the remaining patients was 5.1 months. Rebound growth occurred in 21% of patients after a mean of 4.3 months of therapy. Adverse events occurred in 18.1% of patients and included hypotension in 6, somnolence in 6, wheezing in 4, insomnia, agitation, and/or nightmares in 6, cool hands or night sweats in 2, gastroesophageal reflux in 3, and psoriasis-like rash in 1. All authors reported a favorable outcome with propranolol, but the definition of efficacy was not standardized. Propranolol is an attractive alternative to other treatments for IH. Despite apparent widespread use of this medication, the data are limited, and prospective studies are lacking for this indication. The relatively high rate of adverse effects supports the need for careful monitoring of patients on this therapy. Fastidious reporting of adverse events and objective evaluation of early and late outcomes are necessary to improve our understanding of the use of propranolol for this indication. |
Author | Greene, E. Anne Menezes, Maithilee D. McCarter, Robert Bauman, Nancy M. |
Author_xml | – sequence: 1 givenname: Maithilee D. surname: Menezes fullname: Menezes, Maithilee D. – sequence: 2 givenname: Robert surname: McCarter fullname: McCarter, Robert – sequence: 3 givenname: E. Anne surname: Greene fullname: Greene, E. Anne – sequence: 4 givenname: Nancy M. surname: Bauman fullname: Bauman, Nancy M. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24618432$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22097156$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1LAzEQhoMo2lb_gAcJgsfVfO3XUeonCIpW8LZMdyeSspvUZHvQX2-WVnsQZA7DZJ55Z_KOya51Fgk55uyc8zy_YIxJVZSKcy4Y4zF2yIiXSiZpLt52yWgAkoE4IOMQFrFUKRP75EAIVuY8zUZk8dJDvwrUafrk3dKDda1rqXaezjxC36Hth-a91WB70yK9ww7su3EdULANvcJQe7PsjbMDB_Q5vrrOfGFDp62xpoY2ShloD8mehjbg0SZPyOvN9Wx6lzw83t5PLx-SWmVpn2BTpyVkBbBG5ZAzLBAxU0rLQsWz55LXUEqUc8RY6TnLAAUwIWvMi1RoOSGna92ldx8rDH21cCtv48qqKGMUWbRoQsQaqr0LwaOult504D8rzqrB3eqvu3HoZKO8mnfY_I782BmBsw0AIf5bRztrE7acynihpIjcxZoL8I7b8_5Z_Q0nG5E3 |
CODEN | AORHA2 |
CitedBy_id | crossref_primary_10_1007_s11604_019_00885_5 crossref_primary_10_5301_ejo_5000510 crossref_primary_10_22469_jkslp_2015_26_1_54 crossref_primary_10_1016_j_pcl_2013_04_003 crossref_primary_10_1007_s40136_014_0065_6 crossref_primary_10_1002_lary_24363 crossref_primary_10_1097_SAP_0000000000000390 crossref_primary_10_1097_SAP_0000000000000272 crossref_primary_10_1159_000502947 crossref_primary_10_1007_s00266_015_0515_7 crossref_primary_10_1016_j_jdds_2016_10_002 crossref_primary_10_1016_j_pedex_2012_09_003 crossref_primary_10_1111_dsu_12158 crossref_primary_10_1097_SCS_0000000000004745 crossref_primary_10_1097_PSN_0000000000000105 crossref_primary_10_2146_ajhp140097 crossref_primary_10_1159_000510029 crossref_primary_10_1111_pde_14484 crossref_primary_10_1016_j_ejcsup_2013_07_016 crossref_primary_10_1016_j_ijporl_2021_110688 crossref_primary_10_1111_jdv_14955 crossref_primary_10_1111_bcp_12235 crossref_primary_10_1155_2019_2728952 crossref_primary_10_1590_1984_0462__2019_37_3_00004 crossref_primary_10_1111_jpc_12076 crossref_primary_10_1111_pde_12686 crossref_primary_10_3342_kjorl_hns_2016_59_2_88 crossref_primary_10_1111_pde_12344 crossref_primary_10_1016_j_fsc_2015_04_009 crossref_primary_10_1007_s00431_012_1928_9 crossref_primary_10_1080_14764172_2016_1197402 crossref_primary_10_1016_j_oooo_2012_02_039 crossref_primary_10_1111_1346_8138_15189 crossref_primary_10_1007_s15012_018_2671_3 crossref_primary_10_1007_s40272_021_00477_9 crossref_primary_10_1016_j_siny_2012_04_002 crossref_primary_10_1002_14651858_CD006545_pub3 crossref_primary_10_1016_j_jssdds_2013_04_001 crossref_primary_10_1111_ped_14077 |
Cites_doi | 10.1097/PRS.0b013e3181c2a731 10.1067/mjd.2003.200 10.1111/j.1442-9071.2010.02344.x 10.1056/NEJMc086443 10.1016/j.ijporl.2010.07.025 10.1542/peds.2008-3458 10.1056/NEJMc0708819 10.1002/lary.20633 10.1016/j.ijporl.2009.12.008 10.1016/S0022-3468(83)80043-8 10.1001/archophthalmol.2009.375 10.1002/pbc.22262 10.1001/archderm.1960.01580050009002 10.1016/j.ijporl.2010.05.013 10.1111/j.1525-1470.2009.00975.x 10.1111/j.1525-1470.2009.00977.x 10.1111/j.1468-3083.2010.03603.x 10.1007/s00381-010-1153-7 10.1001/archoto.2010.92 10.1111/j.1442-9071.2010.02327.x 10.1056/NEJM199907153410307 10.1111/j.1525-1470.1997.tb00232.x 10.1016/j.ophtha.2009.08.040 10.1017/S002221511000068X 10.1159/000291300 10.1111/j.1525-1470.2010.01224.x 10.1016/S0037-6337(09)70171-8 10.1542/peds.70.1.30 10.1002/lary.20807 10.1136/bcr.01.2009.1476 10.1001/archdermatol.2010.158 10.1097/MOO.0b013e328332a4eb 10.1016/j.jpeds.2010.04.003 10.1097/00005537-200407000-00017 10.1016/S0022-3476(98)70034-4 10.1016/j.arcped.2003.10.014 10.1016/j.bjps.2010.06.010 10.1016/j.ijporl.2010.06.001 10.1542/peds.2006-0413 10.1016/S0190-9622(97)70183-X 10.1111/j.1468-3083.2009.03261.x 10.1111/j.1525-1470.2008.00626.x 10.1111/j.1365-2133.2009.09597.x 10.1111/j.1525-1470.2009.01081.x 10.1001/archderm.137.9.1208 10.1016/j.ijporl.2010.05.012 10.1542/peds.2007-2767 |
ContentType | Journal Article |
Copyright | 2011 SAGE Publications 2015 INIST-CNRS Copyright Annals Publishing Company Oct 2011 |
Copyright_xml | – notice: 2011 SAGE Publications – notice: 2015 INIST-CNRS – notice: Copyright Annals Publishing Company Oct 2011 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88E 88I 8AF 8AO 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 M0S M1P M2P NAPCQ PQEST PQQKQ PQUKI PRINS Q9U S0X |
DOI | 10.1177/000348941112001010 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Science Database Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic SIRS Editorial |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Central Student ProQuest Central Essentials SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Pharma Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | CrossRef MEDLINE ProQuest Central Student |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1943-572X |
EndPage | 695 |
ExternalDocumentID | 2489374471 10_1177_000348941112001010 22097156 24618432 10.1177_000348941112001010 |
Genre | Comparative Study Review Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NICHD NIH HHS grantid: R21 HD062959 – fundername: NICHD NIH HHS grantid: 5R21HD062959-02 |
GroupedDBID | --- --Z -TM .55 .GJ 0R~ 23M 36B 3HZ 3O- 3V. 4.4 41~ 53G 54M 5GY 5RE 6PF 7RV 7X7 85S 88E 88I 8AF 8AO 8FI 8FJ 8R4 8R5 8RF AABQO AACKU AACMV AACTG AADCB AADUE AAEWN AAGGD AAGMC AAJOX AAJPV AAJQC AAKGS AAKTJ AAMFR AAMGE AANSI AAPEO AAQQG AAQQT AARIX AATAA AATBZ AAUAS AAWLO AAWTL AAYTG ABAWP ABCCA ABDWY ABEIX ABHKI ABKRH ABLUO ABOCM ABPNF ABQKF ABQXT ABRHV ABUWG ABVFX ABYTW ACAEH ACAEP ACARO ACDXX ACFEJ ACGBL ACGFO ACGFS ACGOD ACGZU ACJTF ACLFY ACLZU ACOFE ACOXC ACROE ACSIQ ACTQU ACUAV ACUFS ACUIR ACXKE ACXMB ADBBV ADEIA ADPEE ADQSQ ADRRZ ADTBJ ADUKL AECGH AEDTQ AEKYL AENEX AEPTA AERKM AESMA AESZF AEUHG AEUIJ AEWDL AEWHI AEXNY AFEET AFFNX AFKBI AFKRA AFKRG AFMOU AFQAA AFUIA AFZVT AGKLV AGNHF AGWFA AHMBA AI. AIAGR AIEWD AIIQI AIOMO AJEFB AJUZI AJXAJ ALIPV ALJHS ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV AUTPY AYAKG AZQEC BBRGL BDDNI BENPR BKEYQ BKIIM BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD C45 CBRKF CCGJY CCPQU CORYS DC. DOPDO DV7 DWQXO EBS ECV EJD EMOBN EX3 F5P FEDTE FHBDP FYUFA GNUQQ GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION HCIFZ HMCUK HVGLF HZ~ J5H J8X JCYGO K.F L7B M1P M2P M2Q M4V N4W NAPCQ O9- OHT OVD P2P PCD PQQKQ PROAC PSQYO Q1R Q2X ROL RWL RXW S0X SCNPE SFC SHG SJN SPQ SPV TAE TEORI UDS UGJ UKHRP VH1 WH7 WOW WQ9 X6Y X7M XOL YCW YYY ZGI ZONMY ZPPRI ZRKOI ZSSAH ZXP 08R AAGHA AAICN AAMXZ AANGY AAPBV AAUGY AAWVI ABJOC ABNLC ABPTK AEMII AERUW AGHDM AGTGN AIFIH BFDSU H13 IQODW ZA5 ACJER ALKWR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK K9. PQEST PQUKI PRINS Q9U |
ID | FETCH-LOGICAL-c465t-edc59a68a0d47a70e8eee644f384209b31ca93e3bee09bfb06ae2a023ce7852f3 |
IEDL.DBID | BENPR |
ISSN | 0003-4894 |
IngestDate | Thu Oct 10 18:45:31 EDT 2024 Wed Sep 11 14:15:58 EDT 2024 Sat Sep 28 07:49:40 EDT 2024 Sun Oct 22 16:05:56 EDT 2023 Tue Jul 16 20:53:00 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | hemangioma acebutolol review propranolol Human Description Cardiovascular disease ENT Acebutolol Review Antiarrhythmic agent β-Adrenergic receptor Vascular disease Angioma Treatment Antihypertensive agent Clinical trial Antagonist Propranolol Child Bibliographic review Beta blocking agent |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c465t-edc59a68a0d47a70e8eee644f384209b31ca93e3bee09bfb06ae2a023ce7852f3 |
PMID | 22097156 |
PQID | 898988694 |
PQPubID | 35132 |
PageCount | 10 |
ParticipantIDs | proquest_journals_898988694 crossref_primary_10_1177_000348941112001010 pubmed_primary_22097156 pascalfrancis_primary_24618432 sage_journals_10_1177_000348941112001010 |
PublicationCentury | 2000 |
PublicationDate | 2011-10-01 |
PublicationDateYYYYMMDD | 2011-10-01 |
PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Los Angeles, CA |
PublicationPlace_xml | – name: Los Angeles, CA – name: St. Louis, MO – name: United States – name: Thousand Oaks |
PublicationTitle | Annals of otology, rhinology & laryngology |
PublicationTitleAlternate | Ann Otol Rhinol Laryngol |
PublicationYear | 2011 |
Publisher | SAGE Publications Annals Publishing Compagny SAGE PUBLICATIONS, INC |
Publisher_xml | – name: SAGE Publications – name: Annals Publishing Compagny – name: SAGE PUBLICATIONS, INC |
References | Li, McCahon, Rowe, Martin, Wilcsek, Martin 2010; 38 Enjolras, Gelbert 1997; 14 Holmes, Mishra, Gorst, Liew 2010; 125 Blanchet, Nicollas, Bigorre, Amedro, Mondain 2010; 74 Buckmiller, Dyamenahalli, Richter 2009; 119 Fay, Nguyen, Jakobiec, Meyer-Junghaenel, Waner 2010; 128 Manunza, Syed, Laguda 2010; 162 Finn, Glowacki, Mulliken 1983; 18 Mazereeuw-Hautier, Hoeger, Benlahrech 2010; 157 Rosbe, Suh, Meyer, Maguiness, Frieden 2010; 136 Frieden, Eichenfield, Esterly, Geronemus, Mallory 1997; 37 Bonifazi, Colonna, Mazzotta, Balducci, Laforgia 2008; 18 Barlow, Priebe, Mulliken 1998; 132 Fulkerson, Agim, Al-Shamy, Metry, Izaddoost, Jea 2010; 26 Maturo, Hartnick 2010; 74 Bennett, Fleischer, Chamlin, Frieden 2001; 137 Artman, Grayson, Boerth 1982; 70 Truong, Perkins, Messner, Chang 2010; 74 Kilcline, Frieden 2008; 25 Melo-Gomes 1993; 37 Marsciani, Pericoli, Alaggio, Brisigotti, Vergine 2010; 54 Léauté-Labrèze, de la Roque, Hubiche, Boralevi, Thambo, Taïeb 2008; 358 Bonifazi, Acquafredda, Milano, Montagna, Laforgia 2010; 27 Mistry, Tzifa 2010; 124 Vanlander, Decaluwe, Vandelanotte, Van Geet, Cornette 2010; 98 Siegfried, Keenan, Al-Jureidini 2008; 359 Tan, Itinteang, Leadbitter 2011; 64 Bowers, Graham, Tomlinson 1960; 82 Buckmiller 2009; 17 Enjolras, Brevière, Roger 2004; 11 Buckmiller, Munson, Dyamenahalli, Dai, Richter 2010; 120 Breur, De Graaf, Breugem, Pasmans 2011; 28 Bruckner, Frieden 2003; 48 Blei, Chianese 1999; 14 Canadas, Baum, Lee, Ostrower 2010; 74 Naouri, Schill, Maruani, Bross, Lorette, Rossler 2010; 24 Holland, Frieden, Frommelt, Mancini, Wyatt, Drolet 2010; 146 Drolet, Esterly, Frieden 1999; 341 Haggstrom, Drolet, Baselga 2006; 188 Michaud, Bauman, Burke, Manaligod, Smith 2004; 114 Sans, De la Roque, Berge 2009; 124 Theletsane, Redfern, Raynham, Harris, Prose, Khumalo 2009; 23 Cheng, Gole, Sullivan 2010; 38 Itani, Fakih 2009 Leboulanger, Fayoux, Teissier 2010; 74 Frieden, Drolet 2009; 26 Taban, Goldberg 2010; 117 Lawley, Siegfried, Todd 2009; 26 Chang, Haggstrom, Drolet 2008; 122 bibr35-000348941112001010 Artman M (bibr23-000348941112001010) 1982; 70 bibr37-000348941112001010 bibr39-000348941112001010 bibr14-000348941112001010 bibr10-000348941112001010 bibr29-000348941112001010 bibr1-000348941112001010 bibr31-000348941112001010 bibr33-000348941112001010 bibr54-000348941112001010 bibr3-000348941112001010 bibr5-000348941112001010 bibr7-000348941112001010 bibr24-000348941112001010 bibr22-000348941112001010 bibr19-000348941112001010 bibr21-000348941112001010 bibr26-000348941112001010 bibr25-000348941112001010 bibr27-000348941112001010 bibr28-000348941112001010 bibr17-000348941112001010 bibr16-000348941112001010 bibr20-000348941112001010 Bonifazi E (bibr18-000348941112001010) 2008; 18 bibr6-000348941112001010 bibr38-000348941112001010 bibr36-000348941112001010 bibr13-000348941112001010 Naouri M (bibr44-000348941112001010) 2010; 24 bibr15-000348941112001010 Melo-Gomes JA (bibr12-000348941112001010) 1993; 37 bibr11-000348941112001010 bibr30-000348941112001010 bibr2-000348941112001010 bibr32-000348941112001010 bibr34-000348941112001010 bibr4-000348941112001010 bibr8-000348941112001010 bibr49-000348941112001010 bibr48-000348941112001010 Blei F (bibr9-000348941112001010) 1999; 14 bibr52-000348941112001010 bibr50-000348941112001010 bibr53-000348941112001010 (bibr51-000348941112001010) 2011 bibr41-000348941112001010 bibr46-000348941112001010 bibr40-000348941112001010 bibr47-000348941112001010 bibr42-000348941112001010 bibr45-000348941112001010 bibr43-000348941112001010 |
References_xml | – volume: 128 start-page: 256 year: 2010 end-page: 8 article-title: Propranolol for isolated orbital infantile hemangioma publication-title: Arch Ophthalmol contributor: fullname: Waner – volume: 74 start-page: 323 year: 2010 end-page: 5 article-title: Initial experience using propranolol as the sole treatment for infantile airway hemangiomas publication-title: Int J Pediatr Otorhinolaryngol contributor: fullname: Hartnick – volume: 124 start-page: 1329 year: 2010 end-page: 32 article-title: Use of propranolol to treat multicentric airway haemangioma publication-title: J Laryngol Otol contributor: fullname: Tzifa – volume: 37 start-page: 631 year: 1997 end-page: 7 article-title: Guidelines of care for hemangiomas of infancy publication-title: J Am Acad Dermatol contributor: fullname: Mallory – volume: 146 start-page: 775 year: 2010 end-page: 8 article-title: Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma publication-title: Arch Dermatol contributor: fullname: Drolet – volume: 28 start-page: 169 year: 2011 end-page: 71 article-title: Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: A case report publication-title: Pediatr Dermatol contributor: fullname: Pasmans – volume: 125 start-page: 420 year: 2010 end-page: 1 article-title: Propranolol as first-line treatment for infantile hemangiomas publication-title: Plast Reconstr Surg contributor: fullname: Liew – volume: 136 start-page: 658 year: 2010 end-page: 65 article-title: Propranolol in the management of airway infantile hemangiomas publication-title: Arch Otolaryngol Head Neck Surg contributor: fullname: Frieden – volume: 70 start-page: 30 year: 1982 end-page: 1 article-title: Propranolol in children: Safety-toxicity publication-title: Pediatrics contributor: fullname: Boerth – volume: 132 start-page: 527 year: 1998 end-page: 30 article-title: Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy publication-title: J Pediatr contributor: fullname: Mulliken – volume: 341 start-page: 173 year: 1999 end-page: 81 article-title: Hemangiomas in children publication-title: N Engl J Med contributor: fullname: Frieden – volume: 48 start-page: 477 year: 2003 end-page: 93 article-title: Hemangiomas of infancy publication-title: J Am Acad Dermatol contributor: fullname: Frieden – volume: 26 start-page: 610 year: 2009 end-page: 4 article-title: Propranolol treatment for hemangioma of infancy: Risks and recommendations publication-title: Pediatr Dermatol contributor: fullname: Todd – volume: 358 start-page: 2649 year: 2008 end-page: 51 article-title: Propranolol for severe hemangiomas of infancy publication-title: N Engl J Med contributor: fullname: Taïeb – volume: 120 start-page: 676 year: 2010 end-page: 81 article-title: Propranolol for infantile hemangiomas: Early experience at a tertiary vascular anomalies center publication-title: Laryngoscope contributor: fullname: Richter – volume: 74 start-page: 956 year: 2010 end-page: 8 article-title: Case report: Treatment failure using propranolol for treatment of focal subglottic hemangioma publication-title: Int J Pediatr Otorhinolaryngol contributor: fullname: Ostrower – volume: 14 start-page: 173 year: 1997 end-page: 9 article-title: Superficial hemangiomas: Associations and management publication-title: Pediatr Dermatol contributor: fullname: Gelbert – volume: 117 start-page: 195 year: 2010 end-page: 195.e4 article-title: Propranolol for orbital hemangioma publication-title: Ophthalmology contributor: fullname: Goldberg – volume: 74 start-page: 1043 year: 2010 end-page: 8 article-title: Propranolol for the treatment of airway hemangiomas: A case series and treatment algorithm publication-title: Int J Pediatr Otorhinolaryngol contributor: fullname: Chang – volume: 18 start-page: 894 year: 1983 end-page: 900 article-title: Congenital vascular lesions: Clinical application of a new classification publication-title: J Pediatr Surg contributor: fullname: Mulliken – volume: 82 start-page: 667 year: 1960 end-page: 80 article-title: The natural history of the strawberry nevus publication-title: Arch Dermatol contributor: fullname: Tomlinson – volume: 14 start-page: 146 year: 1999 end-page: 53 article-title: Corticosteroid toxicity in infants treated for endangering hemangiomas: Experience and guidelines for monitoring publication-title: Int Pediatr contributor: fullname: Chianese – volume: 17 start-page: 458 year: 2009 end-page: 9 article-title: Propranolol treatment for infantile hemangiomas publication-title: Curr Opin Otolaryngol Head Neck Surg contributor: fullname: Buckmiller – volume: 27 start-page: 195 year: 2010 end-page: 6 article-title: Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol publication-title: Pediatr Dermatol contributor: fullname: Laforgia – volume: 157 start-page: 340 year: 2010 end-page: 2 article-title: Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis publication-title: J Pediatr contributor: fullname: Benlahrech – volume: 119 start-page: 2051 year: 2009 end-page: 4 article-title: Propranolol for airway hemangiomas: Case report of novel treatment publication-title: Laryngoscope contributor: fullname: Richter – volume: 74 start-page: 959 year: 2010 end-page: 61 article-title: Management of infantile subglottic hemangioma: Acebutolol or propranolol? publication-title: Int J Pediatr Otorhinolaryngol contributor: fullname: Mondain – volume: 188 start-page: 882 year: 2006 end-page: 7 article-title: Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment publication-title: Pediatrics contributor: fullname: Baselga – volume: 26 start-page: 642 year: 2009 end-page: 4 article-title: Propranolol for infantile hemangiomas: Promise, peril, pathogenesis publication-title: Pediatr Dermatol contributor: fullname: Drolet – volume: 162 start-page: 466 year: 2010 end-page: 8 article-title: Propranolol for complicated infantile haemangiomas: A case series of 30 infants publication-title: Br J Dermatol contributor: fullname: Laguda – volume: 137 start-page: 1208 year: 2001 end-page: 13 article-title: Oral corticosteroid use is effective for cutaneous hemangiomas: An evidence-based evaluation publication-title: Arch Dermatol contributor: fullname: Frieden – volume: 54 start-page: 176 year: 2010 article-title: Massive response of severe infantile hepatic hemangioma to propranolol publication-title: Pediatr Blood Cancer contributor: fullname: Vergine – volume: 38 start-page: 554 year: 2010 end-page: 9 article-title: Successful treatment of infantile haemangiomas of the orbit with propranolol publication-title: Clin Experiment Ophthalmol contributor: fullname: Martin – volume: 124 start-page: e423 year: 2009 end-page: e431 article-title: Propranolol for severe infantile hemangiomas: Follow-up report publication-title: Pediatrics contributor: fullname: Berge – volume: 122 start-page: 360 year: 2008 end-page: 7 article-title: Growth characteristics of infantile hemangiomas: Implications for management publication-title: Pediatrics contributor: fullname: Drolet – volume: 26 start-page: 1799 year: 2010 end-page: 805 article-title: Emergent medical and surgical management of mediastinal infantile hemangioma with symptomatic spinal cord compression: Case report and literature review publication-title: Childs Nerv Syst contributor: fullname: Jea – volume: 37 start-page: 35 year: 1993 end-page: 9 article-title: Problems related to systemic glucocorticoid therapy in children publication-title: J Rheumatol Suppl contributor: fullname: Melo-Gomes – volume: 38 start-page: 547 year: 2010 end-page: 53 article-title: Propranolol in the management of periorbital infantile haemangioma publication-title: Clin Experiment Ophthalmol contributor: fullname: Sullivan – volume: 24 start-page: 1109 year: 2010 end-page: 12 article-title: Successful treatment of ulcerated haemangioma with propranolol publication-title: J Eur Acad Dermatol Venereol contributor: fullname: Rossler – volume: 98 start-page: 229 year: 2010 end-page: 31 article-title: Propranolol as a novel treatment for congenital visceral haemangioma publication-title: Neonatology contributor: fullname: Cornette – volume: 64 start-page: 292 year: 2011 end-page: 9 article-title: Low-dose propranolol for infantile hemangioma publication-title: J Plast Reconstr Aesthet Surg contributor: fullname: Leadbitter – volume: 23 start-page: 1465 year: 2009 end-page: 6 article-title: Life-threatening infantile haemangioma: A dramatic response to propranolol publication-title: J Eur Acad Dermatol Venereol contributor: fullname: Khumalo – volume: 114 start-page: 1231 year: 2004 end-page: 6 article-title: Spastic diplegia and other motor disturbances in infants receiving interferon-alpha publication-title: Laryngoscope contributor: fullname: Smith – volume: 74 start-page: 1254 year: 2010 end-page: 7 article-title: Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience publication-title: Int J Pediatr Otorhinolaryngol contributor: fullname: Teissier – year: 2009 article-title: Response of facial haemangioma to oral propranolol publication-title: BMJ Case Reports contributor: fullname: Fakih – volume: 11 start-page: 99 year: 2004 end-page: 107 article-title: Vincristine treatment for function- and life-threatening infantile hemangioma [in French] publication-title: Arch Pediatr contributor: fullname: Roger – volume: 25 start-page: 168 year: 2008 end-page: 73 article-title: Infantile hemangiomas: How common are they? A systematic review of the medical literature publication-title: Pediatr Dermatol contributor: fullname: Frieden – volume: 18 start-page: 185 year: 2008 end-page: 92 article-title: Propranolol in rapidly growing hemangiomas publication-title: Eur J Pediatr Dermatol contributor: fullname: Laforgia – volume: 359 start-page: 2846 year: 2008 end-page: 7 article-title: More on propranolol for hemangiomas of infancy publication-title: N Engl J Med contributor: fullname: Al-Jureidini – ident: bibr50-000348941112001010 – ident: bibr26-000348941112001010 doi: 10.1097/PRS.0b013e3181c2a731 – ident: bibr4-000348941112001010 doi: 10.1067/mjd.2003.200 – ident: bibr45-000348941112001010 doi: 10.1111/j.1442-9071.2010.02344.x – ident: bibr22-000348941112001010 doi: 10.1056/NEJMc086443 – ident: bibr29-000348941112001010 doi: 10.1016/j.ijporl.2010.07.025 – ident: bibr19-000348941112001010 doi: 10.1542/peds.2008-3458 – ident: bibr16-000348941112001010 doi: 10.1056/NEJMc0708819 – ident: bibr17-000348941112001010 doi: 10.1002/lary.20633 – ident: bibr36-000348941112001010 doi: 10.1016/j.ijporl.2009.12.008 – ident: bibr8-000348941112001010 doi: 10.1016/S0022-3468(83)80043-8 – ident: bibr34-000348941112001010 doi: 10.1001/archophthalmol.2009.375 – ident: bibr32-000348941112001010 doi: 10.1002/pbc.22262 – ident: bibr5-000348941112001010 doi: 10.1001/archderm.1960.01580050009002 – ident: bibr41-000348941112001010 doi: 10.1016/j.ijporl.2010.05.013 – ident: bibr30-000348941112001010 doi: 10.1111/j.1525-1470.2009.00975.x – ident: bibr52-000348941112001010 doi: 10.1111/j.1525-1470.2009.00977.x – volume: 24 start-page: 1109 year: 2010 ident: bibr44-000348941112001010 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/j.1468-3083.2010.03603.x contributor: fullname: Naouri M – ident: bibr48-000348941112001010 doi: 10.1007/s00381-010-1153-7 – ident: bibr40-000348941112001010 doi: 10.1001/archoto.2010.92 – ident: bibr46-000348941112001010 doi: 10.1111/j.1442-9071.2010.02327.x – ident: bibr6-000348941112001010 doi: 10.1056/NEJM199907153410307 – ident: bibr7-000348941112001010 doi: 10.1111/j.1525-1470.1997.tb00232.x – ident: bibr33-000348941112001010 doi: 10.1016/j.ophtha.2009.08.040 – ident: bibr37-000348941112001010 doi: 10.1017/S002221511000068X – ident: bibr38-000348941112001010 doi: 10.1159/000291300 – ident: bibr49-000348941112001010 doi: 10.1111/j.1525-1470.2010.01224.x – ident: bibr21-000348941112001010 doi: 10.1016/S0037-6337(09)70171-8 – volume: 70 start-page: 30 year: 1982 ident: bibr23-000348941112001010 publication-title: Pediatrics doi: 10.1542/peds.70.1.30 contributor: fullname: Artman M – ident: bibr25-000348941112001010 doi: 10.1002/lary.20807 – volume-title: Physicians' desk reference year: 2011 ident: bibr51-000348941112001010 – ident: bibr31-000348941112001010 doi: 10.1136/bcr.01.2009.1476 – ident: bibr39-000348941112001010 doi: 10.1001/archdermatol.2010.158 – ident: bibr24-000348941112001010 doi: 10.1097/MOO.0b013e328332a4eb – ident: bibr43-000348941112001010 doi: 10.1016/j.jpeds.2010.04.003 – volume: 14 start-page: 146 year: 1999 ident: bibr9-000348941112001010 publication-title: Int Pediatr contributor: fullname: Blei F – ident: bibr15-000348941112001010 doi: 10.1097/00005537-200407000-00017 – ident: bibr14-000348941112001010 doi: 10.1016/S0022-3476(98)70034-4 – ident: bibr13-000348941112001010 doi: 10.1016/j.arcped.2003.10.014 – ident: bibr28-000348941112001010 doi: 10.1016/j.bjps.2010.06.010 – ident: bibr47-000348941112001010 doi: 10.1016/j.ijporl.2010.06.001 – ident: bibr2-000348941112001010 doi: 10.1542/peds.2006-0413 – ident: bibr10-000348941112001010 doi: 10.1016/S0190-9622(97)70183-X – ident: bibr53-000348941112001010 – ident: bibr20-000348941112001010 doi: 10.1111/j.1468-3083.2009.03261.x – ident: bibr1-000348941112001010 doi: 10.1111/j.1525-1470.2008.00626.x – volume: 18 start-page: 185 year: 2008 ident: bibr18-000348941112001010 publication-title: Eur J Pediatr Dermatol contributor: fullname: Bonifazi E – ident: bibr27-000348941112001010 doi: 10.1111/j.1365-2133.2009.09597.x – volume: 37 start-page: 35 year: 1993 ident: bibr12-000348941112001010 publication-title: J Rheumatol Suppl contributor: fullname: Melo-Gomes JA – ident: bibr35-000348941112001010 doi: 10.1111/j.1525-1470.2009.01081.x – ident: bibr11-000348941112001010 doi: 10.1001/archderm.137.9.1208 – ident: bibr42-000348941112001010 doi: 10.1016/j.ijporl.2010.05.012 – ident: bibr3-000348941112001010 doi: 10.1542/peds.2007-2767 – ident: bibr54-000348941112001010 |
SSID | ssj0004502 |
Score | 2.263372 |
SecondaryResourceType | review_article |
Snippet | Objectives:
Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at... Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation... Objectives: Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at... |
SourceID | proquest crossref pubmed pascalfrancis sage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 686 |
SubjectTerms | Age Factors Antiarythmic agents Biological and medical sciences Cardiovascular system Child Child, Preschool Hemangioma - drug therapy Humans Medical sciences Otorhinolaryngology. Stomatology Pharmacology. Drug treatments Prednisolone - therapeutic use Propranolol - administration & dosage Propranolol - adverse effects Propranolol - therapeutic use Recurrence Treatment Outcome |
Title | Status of Propranolol for Treatment of Infantile Hemangioma and Description of a Randomized Clinical Trial |
URI | https://journals.sagepub.com/doi/full/10.1177/000348941112001010 https://www.ncbi.nlm.nih.gov/pubmed/22097156 https://www.proquest.com/docview/898988694 |
Volume | 120 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fSxwxEB6qghSK2NbqVj3y0IdCWcwm2WzyJCrKtaCIKNzbkU2yoni7p3e-9K_v5C7RHv543OxOdplJZr5sJt8A_BDcFXXFda5FoXJRcplr52zuqGfOCocIP5xGPj2T_SvxZ1AOYm7OJKZVJp84c9Sus-Ef-V4oc6iU1GJ_fJ-HolFhczVW0FiCFVaIsEu7cnh8dn7xH104ZalknlBapFMz1Yy1kYcmnOtsRrRGFyLTp7GZoJKaeXWL1-DnQurXLBqdrMNahJHkYG73z_DBt19g9TRulH-F2wAiHyeka8j5QzfG_tHJ3RFEqOQypZaHm7_bBlWLnoH0_ci01zfdyBDTOoLr0eRPwnOGXGBrN7r56x2JXKJ32BWO3g24Ojm-POrnsaxCboUsp7l3ttRGKkOdqExFvfLeIyxquBKM6poX1mjuee09XjU1lcYzg7Hd-kqVrOHfYLntWr8FBMU12qQ2DatDNDS0Kbg1zkonOaMqg19JpcPxnD1jWCSC8RcGyKC3oPUnkcB5pwRnGWwnMwzjVJsMnwZGBptzyzzLscCQVcoMfgZTPcu8_Q3f333FNnxkKQew2IHl6cOj30VQMq17sFQNql4cgP8AQaTcEA |
link.rule.ids | 315,786,790,12083,21416,27955,27956,31752,33777,43343,43838,74100,74657 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dT9swED9tRdomTWjfBDbmhz1MmqI5tuPYT9OYQGWjFUJF4i1ybAcx0aTQ8rK_nnNrw6p9PMbJOdGdffdzfP4dwAfBXdFUXOdaFCoXJZe5ds7mjnrmrHCI8MNp5NFYDk_F97PyLObmzGNaZfKJS0ftehv-kX8OZQ6Vklp8mV3loWhU2FyNFTQewkZg3FQD2NjbHx-f_EYXTlkqmSeUFunUTLVkbeShCec6WxKt0bXI9HRm5qikdlXd4m_wcy31axmNDp7BZoSR5OvK7s_hge9ewKNR3Ch_CT8DiLyZk74lx9f9DPtHJ3dJEKGSSUotDzcPuxZVi56BDP3UdOcX_dQQ0zmC69HkT8Jzhpxgaz-9-OUdiVyil9gVjt5XcHqwP_k2zGNZhdwKWS5y72ypjVSGOlGZinrlvUdY1HIlGNUNL6zR3PPGe7xqGyqNZwZju_WVKlnLX8Og6zu_BQTFNdqkMS1rQjQ0tC24Nc5KJzmjKoNPSaX1bMWeUReJYPwPA2Swu6b1O5HAeacEZxnsJDPUcarN67uBkcGblWXu5VhgyCplBh-Dqe5l_v0N2_99xXt4PJyMjuqjw_GPHXjCUj5g8RYGi-sb_w4ByqLZjcPwFqOX3h8 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB5BkSqkCvEmFIoPHJBQVMd2HPuEELDaAq0q1Ep7ixw_UFE32Xa3F34946zdsuJxjJNJopnxzCQefx_Aa8Fd1TVcl1pUqhQ1l6V2zpaOeuascFjhx93Ih0dyeio-z-pZghRaprbKHBPHQO0GG_-R70eaQ6WkFvshdUUcf5y8W1yUkUAqLrQmNo3bcAeTJI0sDs2s-Q04nLJMnieUFnn_TDPiN_I4hLOejZBrdCNH7SzMEtUV1jwXfytEN5rAxrw0uQ_3UkFJ3q894AHc8v1D2D5MS-aP4EcsJ6-WZAjk-HJY4P0x3J0TrFXJSW4yjycP-oBKxhhBpn5u-u9nw9wQ0zuCX6Y5ssTrDPmGo8P87Kd3JKGKnuOt0I8fw-nk08mHaZkIFkorZL0qvbO1NlIZ6kRjGuqV9x4LpMCVYFR3vLJGc8877_EodFQazwxmeesbVbPAn8BWP_T-GRAU12idzgTWxbxoaKi4Nc5KJzmjqoC3WaXtYo2j0VYZavwPAxSwt6H1a5GIfqcEZwXsZjO0adIt22sXKeDp2jI3cixiZdWygDfRVDcy_36H5_99xCvYRv9rvx4cfdmFuyw3BlYvYGt1eeVfYqWy6vZGH_wFQ_Lg3A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Status+of+Propranolol+for+Treatment+of+Infantile+Hemangioma+and+Description+of+a+Randomized+Clinical+Trial&rft.jtitle=Annals+of+otology%2C+rhinology+%26+laryngology&rft.au=MENEZES%2C+Maithilee+D&rft.au=MCCARTER%2C+Robert&rft.au=GREENE%2C+E.+Anne&rft.au=BAUMAN%2C+Nancy+M&rft.date=2011-10-01&rft.pub=Annals+Publishing+Compagny&rft.issn=0003-4894&rft.eissn=1943-572X&rft.volume=120&rft.issue=10&rft.spage=686&rft.epage=695&rft_id=info:doi/10.1177%2F000348941112001010&rft.externalDBID=n%2Fa&rft.externalDocID=24618432 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4894&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4894&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4894&client=summon |